Anaplastic Large Cell Lymphoma - 61 Studies Found

Completed : Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
: Anaplastic Large-Cell Lymphoma
: 2004-03-12
: Drug: SGN-30 (anti-CD30 mAb)
Terminated : SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
: Anaplastic Large Cell Lymphoma
: 2006-08-16
:
  • Drug: Cyclophosphamide Given I
Withdrawn : A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
: Systemic Anaplastic Large-Cell Lymphoma
: 2015-06-30
: Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc
Active, not recruiting : Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
: Anaplastic Large-cell Lymphoma
: 2013-07-01
: Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion
Terminated : Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
:
  • Anaplastic Large Cell Lymphoma
  • Recurrent Childhood : 2006-07-19
    :
    • Biological: monoclonal antibody SGN-30

Not yet recruiting : Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
:
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • Systemic : 2016-03-29
    :
    • Drug: Brentuximab Vedotin Give
Recruiting : Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
: 2014-04-17
: Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion
Active, not recruiting : Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
:
  • Hodgkin Lymphoma
  • Anaplastic Large Cell Lymphoma

: 2012-08-02
:
  • Drug: Brentuximab Vedotin Dose
Completed : Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
:
  • Hodgkin Lymphoma
  • Anaplastic Large Cell Lymphoma

: 2008-01-21
: Biological: XmAb2513 Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0,
Completed : A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
:
  • Hodgkin Lymphoma
  • Anaplastic Large-cell Lymphoma

: 2013-09-23
:
  • Drug: brentuximab vedotin Bren
Next >>>